FindTrial
Sign In

effect of everolimus on adult polycystic nephropaty; a study pilot - PolEver

effect of everolimus on adult polycystic nephropaty; a study pilot - PolEver

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2007-001503-38-IT
Enrollment
Unknown
Registered
2008-06-03
Start date
2008-06-05
Completion date
Unknown
Last updated
2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Autosomal Dominant Plycystic Kidney Disease MedDRA version: 9.1 Level: LLT Classification code 10010607 Term: Congenital renal cyst

Interventions

Trade Name: CERTICAN Pharmaceutical Form: Tablet INN or Proposed INN: Everolimus Concentration unit: mg milligram(s) Concentration type: equal Concentration number: .75- Pharmaceutical form of the pla

Sponsors

AZIENDA OSPEDALIERA PROVINCIALE DI LECCO
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: male and female ADPKD mayor 18 , estimated GFR between 30 and 60 mil/min/1.73 mq, almost 1 creatinine value/year in the previous 2 years, progressive renal insufficiency Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: female of childbearing potential who is planning to become pregnant. granulocytopenia or thrombocytopenia,hyperlipidemia

Design outcomes

Primary

MeasureTime frame
Main Objective: the aim of the study is to investigate wheter everolimus ratards cyst growth and slow renal funcional deterioration in patients with ADPKD;Secondary Objective: a positiv influence of everolimus on ADPKD in adults;Primary end point(s): glomerular filtration rate at any visit—

Countries

Italy

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026